Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
IN8bio, Inc. is a clinical-stage biotechnology company focused on developing novel cell-based immunotherapies for the treatment of cancer. The company operates within the biotechnology and oncology therapeutics industries, with a specialized emphasis on leveraging gamma-delta (γδ) T cell biology to address cancers with high unmet medical need. Its therapeutic approach is centered on using genetically modified or activated immune cells designed to target malignant cells while minimizing off-tumor toxicity.
The company’s primary revenue driver is research and development activity related to its proprietary cell therapy candidates, as IN8bio does not currently generate commercial product revenue. Its lead programs target glioblastoma multiforme (GBM) and hematologic malignancies such as acute leukemia, particularly in post–stem cell transplant settings. IN8bio was founded in 2015 and advanced its platform through preclinical and early clinical development before becoming a publicly traded company in 2021, following its initial public offering on the Nasdaq Capital Market.
Business Operations
IN8bio operates as a single-reportable operating segment focused on the discovery, development, and clinical advancement of γδ T cell–based therapies. The company’s core assets include its proprietary gamma-delta T cell engineering platform and a pipeline of autologous and allogeneic cell therapy candidates designed to enhance immune-mediated tumor targeting. Its programs are primarily in Phase 1 clinical development, with activities centered on clinical trial execution, manufacturing process development, and regulatory engagement.
Operationally, IN8bio conducts its activities primarily through internal research teams and external partnerships with clinical research organizations, academic medical centers, and specialized cell manufacturing providers. The company does not report material subsidiaries or joint ventures based on publicly available filings. Data inconclusive based on available public sources regarding any revenue-generating commercial partnerships.
Strategic Position & Investments
IN8bio’s strategic direction is focused on advancing first-in-class γδ T cell therapies into and through early-stage clinical trials, with the goal of demonstrating safety and preliminary efficacy in difficult-to-treat cancers. Growth initiatives center on expanding its clinical pipeline, optimizing cell engineering techniques, and exploring additional oncology indications where γδ T cells may offer a therapeutic advantage over conventional alpha-beta T cell approaches.
The company’s major investments are concentrated in internal research and development, clinical trial infrastructure, and intellectual property protection. IN8bio has not disclosed any large-scale acquisitions or ownership of notable portfolio companies. Its technology platform positions the company within the emerging field of next-generation cellular immunotherapy, particularly in areas where immune evasion and central nervous system penetration are critical challenges.
Geographic Footprint
IN8bio is headquartered in North America, with its principal executive offices located in the United States. The company’s operational footprint is primarily domestic, reflecting its current clinical-stage status and focus on U.S.-based regulatory pathways and clinical trial sites.
While its corporate presence is U.S.-centric, IN8bio’s clinical and scientific activities involve collaborations with academic and clinical institutions that may include international research participation. Data inconclusive based on available public sources regarding material long-term operational facilities or commercial activities outside the United States.
Leadership & Governance
IN8bio was co-founded by physician-scientists with experience in oncology, immunology, and clinical research, shaping a leadership philosophy centered on translational science and disciplined clinical execution. The company is governed by a board of directors with backgrounds in biotechnology, drug development, and corporate governance, consistent with public company standards.
Key members of the executive leadership team include:
- William Ho, MD, PhD – President and Chief Executive Officer
- Mark Andrews – Chief Financial Officer
- Michael R. Jensen, MD – Chief Medical Officer
- Jill Pantaleo – Senior Vice President, Operations
The leadership team emphasizes advancing innovative immunotherapies through rigorous clinical validation while maintaining regulatory compliance and financial stewardship appropriate for a publicly listed biotechnology company.